Bio-Matrix Scientific Group Inc plans to acquire patented cancer gene-silencing technology for breast cancer
Feb 27, 2013 (Menafn - M2 EQUITYBITES via COMTEX) --Biotechnology company Bio-Matrix Scientific Group Inc (pinksheets:BMSN) reported on Tuesday a Letter of Intent (LOI) to acquire patented intellectual property covering a novel means of treating breast cancer by augmenting the immune system using a "gene silencing" approach.
This LOI was initiated by the company's wholly owned subsidiary, Regen BioPharma Inc.
The company said that the technology has been published in peer-reviewed journals by Professor Min, which documents its capacity of reducing tumours in melanoma (Zheng et al. J Immunol. 2006 Oct 15;177(
:5639-46) and breast cancer models (Zheng et al. Int J Cancer. 2013 Feb 15;132(4):967-77).
According to the company, the gene silencing therapy was developed with the help pf USD1.5m of grant money at the University of Western Ontario, Canada. This approach offers the possibility of destroying tumours in a non-toxic manner through leveraging the body's own immune system to recognise the cancer as "foreign" and subsequently eradicating it.
Additionally, the transaction contemplated by the LOI is subject to the execution of one or more definitive agreements on terms and conditions mutually acceptable to the parties.
Comments on this story may be sent to info@m2.com
(C)1994-2013 M2 COMMUNICATIONS http://www.m2.com
(0)
(0)
